论文部分内容阅读
灭滴灵于1972年首先由 Tally 等用于治疗全身性厌氧菌感染。此后,证实灭滴灵在体外对抗厌氧菌有很好的作用,临床疗效也很好。但是,1979年 San-ders 等认为单用灭滴灵对厌氧菌的胸膜-肺部感染疗效不佳。同年,Perlino 证实,治疗肺脓疡时,灭滴灵疗效低于氯洁霉素。1981年 Collier 等研究证实,治疗腹腔内感染时,就此2药的疗效和毒性而言,灭滴灵和氯洁霉素相同。与治疗厌氧菌的其他药物相比,灭滴灵的潜在优越性在于此药有很好的穿透性,能进入身体所有组织、体液及体腔中。本文研究灭滴灵静脉用药治疗厌氧菌的各种感染。
Melphalan was first used by Tally et al in 1972 to treat systemic anaerobic infections. Since then, metronidazole confirmed in vitro against anaerobic bacteria have a good effect, clinical efficacy is also very good. However, San-ders et al. In 1979 concluded that metronidazole alone was not effective in treating pleuropulmonary infection of anaerobic bacteria. In the same year, Perlino confirmed that metronidazole was less effective than clindamycin in the treatment of lung abscesses. Collier and other studies in 1981 confirmed that the treatment of intra-abdominal infections, the efficacy and toxicity of this two drugs, metronidazole and clindamycin the same. The potential advantage of metronidazole over other drugs used to treat anaerobes is that the drug has good penetrating power and can enter all body tissues, body fluids and body cavities. This article studies the metronidazole intravenous drug treatment of various infections of anaerobic bacteria.